MUSCLE study - Mitochondrial dysfUnction: a key player in doxorubicin-induced Skeletal and Cardiac muscLE damage?
- Conditions
- Non-Hodgkin lymphoma10025320
- Registration Number
- NL-OMON53341
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 12
• Age >= 18 years
• Patients with large B-cell lymphoma or T-cell lymphoma scheduled for 6
full-dose cycles of 1st line immunochemotherapy with cyclophosphamide,
doxorubicin, vincristine and prednisone with or without rituximab ((reversed)
(R-)CHOP).
• WHO-performance score 0-2.
• Patients with sufficient Dutch writing and reading skills.
• Written informed consent
• Contra-indications for 7T MR scanning
• Any circumstances that would impede adherence to study requirements or
ability to give informed consent.
• Medical disorders affecting mitochondrial function; e.g., spinal muscular
atrophy.
• (Other) relevant medical disorders; e.g., comorbidities affecting exercise
tolerance.
• Being under examination for non-diagnosed disease at the time of
investigation.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method